New Molecular, Biological, and Immunological Agents Inducing Hypophysitis

Area of Science:

• Endocrinology
• Immunology
• Oncology

Background:

• Hypophysitis is a rare autoimmune condition affecting the pituitary gland.
• Immunomodulatory drugs, particularly those used in cancer therapy, are increasingly recognized causes.
• Anti-cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibodies are associated with a notable prevalence of hypophysitis.

Purpose of the Study:

• To review current information on hypophysitis induced by novel molecular, biological, and immunological agents.
• To highlight the association between cancer immunotherapies and hypophysitis.
• To discuss diagnostic challenges and management strategies.

Main Methods:

• Literature review of hypophysitis associated with new immunomodulatory and biological agents.
• Analysis of reported prevalence rates for different drug classes.
• Discussion of diagnostic criteria and pathophysiological insights.

Main Results:

• Hypophysitis is a recognized side effect of anti-CTLA-4 antibody therapy (0-18% prevalence).
• Hypophysitis associated with anti-programmed cell death protein-1 (anti-PD-1) antibodies is less frequent (0-0.8%).
• No cases of hypophysitis have been reported with molecular targeted agents.

Conclusions:

• Hypophysitis diagnosis remains primarily clinical, as serological markers are not consistently sensitive.
• The pathophysiology of drug-induced hypophysitis is not fully understood.
• Management typically involves dose adjustment of the causative agent and pituitary hormone replacement therapy.